Last reviewed · How we verify
BLU-808
BLU-808 is a potent and selective KIT inhibitor.
BLU-808 is a potent and selective KIT inhibitor. Used for Gastrointestinal stromal tumor (GIST).
At a glance
| Generic name | BLU-808 |
|---|---|
| Sponsor | Blueprint Medicines Corporation |
| Drug class | KIT inhibitor |
| Target | KIT |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BLU-808 selectively targets and inhibits the KIT receptor tyrosine kinase, which is involved in the pathogenesis of various cancers.
Approved indications
- Gastrointestinal stromal tumor (GIST)
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) (PHASE2)
- Study of BLU-808 in Allergic Rhinoconjunctivitis (PHASE2)
- Study of BLU-808 in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BLU-808 CI brief — competitive landscape report
- BLU-808 updates RSS · CI watch RSS
- Blueprint Medicines Corporation portfolio CI